שאלה לדוקטור

, אני בתהליך הרזיה איטי וסובלת מבעיות רפואיות (תת פעילות בבלוטת התריס ומטופלת באלטרוקסין, הרופא שלי המליץ לי על כדורים בשם "גלוקופאז'" שאמורים לעזור גם לירידה במשקל למרות שאינני סובלת מסכרת. רופא נוסף שהתייעצתי איתו לא המליץ מחוסר ידע על האספקט הזה של הכדורים. האם יש סיכון בשימוש בכדורים אלה לאנשים שאינם חולי סכרת, ?

משתמשים לירידה במשקל ולמניעת סוכרת תופעות הלוואי: Glucophage Side Effects / Metformin Glucophage Online Information Glucophage Side Effects Glucophage Overdose Glucophage Dosage Glucophage Patient Information Glucophage Warnings Glucophage Drug Pharmacology SPONSORED GLUCOPHAGE SITES Lactic Acidosis: See WARNINGS, PRECAUTIONS and OVERDOSAGE. Gastrointestinal Reactions: Gastrointestinal symptoms (diarrhea, nausea, vomiting, abdominal bloating, flatulence, and anorexia) are the most common reactions to metformin HCl and are approximately 30% more frequent in patients on metformin HCl monotherapy than in placebo-treated patients, particularly during initiation of metformin HCl therapy. These symptoms are generally transient and resolve spontaneously during continued treatment. Occasionally, temporary dose reduction may be useful. In controlled trials, metformin HCl was discontinued due to gastrointestinal reactions in approximately 4% of patients. Because gastrointestinal symptoms during therapy initiation appear to be dose-related, they may be decreased by gradual dose escalation and by having patients take metformin HCl with meals (see DOSAGE AND ADMINISTRATION). Because significant diarrhea and/or vomiting may cause dehydration and prerenal azotemia, under such circumstances, metformin HCl should be temporarily discontinued. For patients who have been stabilized on metformin HCl, nonspecific gastrointestinal symptoms should not be attributed to therapy unless intercurrent illness or lactic acidosis have been excluded. Special Senses: During initiation of metformin HCl therapy, approximately 3% of patients may complain of an unpleasant or metallic taste, which usually resolves spontaneously. Dermatologic Reactions: The incidence of rash/dermatitis in controlled clinical trials was comparable to placebo for metformin HCl monotherapy and to sulfonylurea for metformin HCl/sulfonylurea therapy. Hematologic: (See also PRECAUTIONS.) During controlled clinical trials of 29 weeks duration, approximately 9% of patients on metformin HCl monotherapy and 6% of patients on metformin HCl/sulfonylurea therapy developed asymptomatic subnormal serum vitamin B12 levels; serum folic acid levels did not decrease significantly. However, only five cases of megaloblastic anemia have been reported with metformin administration (none during U.S. clinical studies) and no increased incidence of neuropathy has been observed. Therefore, serum B12 levels should be appropriately monitored or periodic parenteral B12 supplementation considered. DRUG ABUSE AND DEPENDENCE Metformin HCl possesses no pharmacodynamic properties, either primary or secondary, which could be expected to result in abuse as a recreational drug or addiction. Drug Interactions Glyburide: In a single dose interaction study in NIDDM subjects, co-administration of metformin and glyburide did not result in any changes in either metformin pharmacokinetics or pharmacodynamics. Decrease in glyburide AUC and Cmax were observed, but were highly variable. The single-dose nature of this study and the lack of correlation between glyburide blood levels and pharmacodynamic effects, makes the clinical significance of this interaction uncertain (see DOSAGE AND ADMINISTRATION, Concomitant Metformin HCl and Oral Sulfonylurea Therapy). Furosemide: A single-dose, metformin-furosemide drug interaction study in healthy subjects demonstrated that pharmacokinetic parameters of both compounds were affected by co-administration. Furosemide increased the metformin plasma and blood Cmax by 22% and blood AUC by 15%, without any significant change in metformin renal clearance. When administered with metformin, the Cmax and AUC of furosemide were 31% and 12% smaller, respectively, than when administered alone, and the terminal half-life was decreased by 32%, without any significant change in furosemide renal clearance. No information is available about the interaction of metformin and furosemide when co-administered chronically. Nifedipine: A single-dose, metformin-nifedipine drug interaction study in normal healthy volunteers demonstrated that co-administration of nifedipine increased plasma metformin Cmax and AUC by 20% and 9%, respectively, and increased the amount excreted in the urine. Tmax and half-life were unaffected. Nifedipine appears to enhance the absorption of metformin. Metformin had minimal effects on nifedipine. Cationic Drugs: Cationic drugs (e.g., amiloride, digoxin, morphine, procainamide, quinidine, quinine, ranitidine, triamterene, trimethoprim, and vancomycin) that are eliminated by renal tubular secretion theoretically have the potential for interaction with metformin by competing for common renal tubular transport systems. Such interaction between metformin and oral cimetidine has been observed in normal healthy volunteers in both single- and multiple-dose, metformin-cimetidine drug interaction studies, with a 60% increase in peak metformin plasma and whole blood concentrations and a 40% increase in plasma and whole blood metformin AUC. There was no change in elimination half-life in the single-dose study. Metformin had no effect on cimetidine pharmacokinetics. Although such interactions remain theoretical (except for cimetidine), careful patient monitoring and dose adjustment of metformin HCl and/or the interfering drug is recommended in patients who are taking cationic medications that are excreted via the proximal renal tubular secretory system. Other: Certain drugs tend to produce hyperglycemia and may lead to loss of glycemic control. These drugs include thiazide and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. When such drugs are administered to a patient receiving metformin HCl, the patient should be closely observed to maintain adequate glycemic control. In healthy volunteers, the pharmacokinetics of metformin and propranolol and metformin and ibuprofen were not affected when co-administered in single-dose interaction studies. Metformin is negligibly bound to plasma proteins and is, therefore, less likely to interact with highly protein-bound drugs such as salicylates, sulfonamides, chloramphenicol, and probenecid, as compared to the sulfonylureas, which are extensively bound to serum proteins.

אתה מוכן לומר לי בקצרה האם כדאי להשתמש בתרופה למטרת הרזיה למרות שאינני סובלת מסוכרת?